Drug Profile
Ceftolozane/tazobactam - Merck Sharp & Dohme
Alternative Names: CXA-101/tazobactam; CXA-101/YTR-830H; CXA-201; MK-7625A; Tazobactam/ceftolozane; Tazobactam/CXA-101; ZerbaxaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer M. D. Anderson Cancer Center; Merck Sharp & Dohme
- Class 2 ring heterocyclic compounds; Anti-infectives; Anti-inflammatories; Antibacterials; Cephalosporins; Small molecules; Sulfones; Triazoles
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
- Registered Pyelonephritis
- Phase II Bacterial infections
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Nosocomial-pneumonia(In adolescents, In children, In infants, In neonates) in Estonia (IV, Infusion)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Nosocomial-pneumonia(In adolescents, In children, In infants, In neonates) in Spain (IV, Infusion)
- 31 Jul 2022 Merck Sharp & Dohme re-initiates phase I trial in Nosocomical pneumonia and Ventilator-associated-pneumonia in Estonia, Greece, Russia, Spain, Ukraine, US (NCT04223752)